Bruno Gomes Email & Phone Number

Porto, Pt

Porto, Portugal

Have co-developed and implemented a lab for the discovery of VHH and another antibody-like scaffold for the application in high-value products in the biotech field.

Have been involved in planning, writing, FTE allocation and budgeting of antibody and antibody-like scaffold discovery programs for immuno-oncology and infectious diseases, for therapeutic and diagnostic purposes.

Cambridge, United Kingdom

Lead position in implementing and improving selection, screening and sequenceoptimization strategies to characterize Affimer® leads using Phage Display technologyand high throughput screening techniques. Was also responsible for discovery andtechnology development projects.

Porto Area, Portugal

In this CRO company, I managed a team aiming the discovery of antibody fragment drugcandidates with determined characteristics, designing, planning, managing and runningseveral projects for a key client.

Porto Area, Portugal

In this startup CRO company, I designed and ran antibody discovery experiments in orderto identify antibody fragment candidates of various formats, from immune libraryconstruction to characterization of lead candidates. I was also involved in severaltechnology and tool development projects.

I worked at the lead identification and characterization team for the discovery ofNanobodies® (VHH), the first and at that time the only company with rights to developcamelid single domain antibodies for therapeutic purposes. This was my first industryexperience where I gained an outstanding experience in a fast-paced environmentdeveloping high quality scientific data.

In my MSc project I develop and immunoassay for detection of an antibiotic inenvironmental samples. In this project I was first introduced to antibody discovery using ahuman scFv library and Phage Display technology, recombinant protein cloning,expression and purification and assay development.

Bsc, Microbiology

Msc, Molecular Microbiology

Selection and characterization of scFv antibodies against ciprofloxacin by phage display